Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Setting the stage for biosimilar monoclonal antibodies

Nature Biotechnology volume 30, pages 1179–1185 (2012)Cite this article

Subjects

With the first marketing authorization application for a biosimilar monoclonal antibody now under consideration at the European Medicines Agency, what are the critical issues for regulators?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Regulatory history of biosimilar mAbs in Europe.
Figure 2: Regulatory issues and market uptake for biosimilars in the EU.

References

  1. European Medicines Agency. Applications for New Human Medicines Under Evaluation by the Committee for Medicinal Products for Human Use: April 2012 <http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/04/WC500125365.pdf> (EMA, London, 2012).

  2. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies—Non-Clinical and Clinical Issues EMA/CHMP/BMWP/403543/2010. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf> (EMA, London, 2012).

  3. Schneider, C.K. & Kalinke, U. Nat. Biotechnol. 26, 985–990 (2008).

    Article  CAS  Google Scholar 

  4. European Medicines Agency. EMEA Workshop on Monoclonal Antibodies, London, UK. <http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2009/11/event_detail_000013.jsp&mid=WC0b01ac058004d5c3> (2 July 2009).

  5. European Medicines Agency. Concept Paper on the Development of a Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies EMEA/CHMP/BMWP/632613/2009. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/11/WC500014438.pdf> (EMA, London, UK, 2009).

  6. European Medicines Agency. European Medicines Agency Workshop on Biosimilar Monoclonal Antibodies and Immunogenicity of Monoclonal Antibodies, London, UK. <http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2011/10/event_detail_000538.jsp&mid=WC0b01ac058004d5c3&murl=menus/news_and_events/news_and_events.jsp> (24 October 2011).

  7. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies EMA/CHMP/BMWP/403543/2010. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099361.pdf> (EMA, London, 2010).

  8. Weise, M. et al. Nat. Biotechnol. 29, 690–693 (2011).

    Article  CAS  Google Scholar 

  9. Schneider, C.K. et al. Nat. Biotechnol. 30, 748–749 (2012).

    Article  Google Scholar 

  10. Schneider, C.K. & Schäffner-Dallmann, G. Nat. Rev. Drug Discov. 7, 893–899 (2008).

    Article  CAS  Google Scholar 

  11. European Medicines Agency. Multidisciplinary Guidelines: Biosimilar. <http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c> (EMA, London, 2012).

  12. European Medicines Agency. Guideline on Non-Clinical and Clinical Development of Similar Biological Medicinal Products Containing Low-Molecular-Weight-Heparins EMEA/CHMP/BMWP/118264/2007. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003927.pdf> (EMA, London, UK, 2009).

  13. European Medicines Agency. Guidance on Similar Medicinal Products Containing Recombinant Human Soluble Insulin EMEA/CHMP/BMWP/32775/2005. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003957.pdf> (EMA, London, 2006).

  14. European Medicines Agency. Guidance on Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor EMEA/CHMP/BMWP/31329/2005. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003955.pdf> (EMA, London, 2006).

  15. European Medicines Agency. Overview of comments received on 'Guideline on similar biological medicinal products containing monoclonal antibodies' EMA/205886/2012. <http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500128687.pdf> (EMA, London, 2012).

  16. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins As Active Substance: Non-Clinical and Clinical Issues EMEA/CHMP/BMWP/42832/2005. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf> (EMA, London, 2006).

  17. Schiestl, M. et al. Nat. Biotechnol. 29, 310–312 (2011).

    Article  CAS  Google Scholar 

  18. Chirino, A.J. & Mire-Sluis, A. Nat. Biotechnol. 22, 1383–1391 (2004).

    Article  CAS  Google Scholar 

  19. European Parliament and Council. Off. J. European Union 3L348, 74–99 (2010).

  20. European Medicines Agency. European Public Assessment Report. <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125> (EMA, London, 2012).

  21. English, V. RAJ Pharma Markets. 2007, 173–174 (2007).

    Google Scholar 

  22. European Medicines Agency. European Public Assessment Reports for Filgrastim ratiopharm, Ratiograstim, Biograstim, Tevagrastim. <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125> (EMA, London, 2008).

  23. Weise, M. et al. Blood published online, doi:10.1182/blood-2012-04-425744 (23 October 2012).

Download references

Acknowledgements

The authors wish to thank P. Richardson from the EMA for providing the regulatory description of dossier requirements for biosimilars that we used for Figure 2a, D. Mannion from the Danish Health and Medicines Authority for helpful comments on the manuscript, and K. Desser from the Danish Health and Medicines Authority for providing the figures from the Danish Register of Medicinal Products Statistics. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties.

Author information

Authors and Affiliations

  1. Christian K. Schneider is at the Danish Health and Medicines Authority, Copenhagen, Denmark, the Working Party on Biosimilar Medicinal Products, European Medicines Agency (EMA), London, UK, and the Twincore Centre for Experimental and Clinical Infection Research, Hannover, Germany.,

    Christian K Schneider

  2. Camille Vleminckx, Iordanis Gravanis and Falk Ehmann are at the EMA, London, UK.,

    Camille Vleminckx, Iordanis Gravanis & Falk Ehmann

  3. Jean-Hugues Trouvin is at the Biologicals Working Party, EMA, London, and the School of Pharmacy, Paris Descartes University, Paris, France.,

    Jean-Hugues Trouvin

  4. Martina Weise is at the Working Party on Biosimilar Medicinal Products, EMA, London, UK, and the Bundesinstitut fuer Arzneimittel und Medizinprodukte, Bonn, Germany.,

    Martina Weise

  5. Steffen Thirstrup is at the Danish Health and Medicines Authority, Copenhagen, Denmark, and the European Commission Project Group on Access and Uptake of Biosimilars and Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark.,

    Steffen Thirstrup

Authors
  1. Christian K Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camille Vleminckx
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iordanis Gravanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Falk Ehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Hugues Trouvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martina Weise
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Steffen Thirstrup
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian K Schneider.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schneider, C., Vleminckx, C., Gravanis, I. et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 30, 1179–1185 (2012). https://doi.org/10.1038/nbt.2447

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2447

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research